Efforts to Countermeasures Against New Coronavirus Infections
May 21, 2020
Japan Pharmaceutical Manufacturers Association
Chairman Joji Nakayama
We would like to express our deepest condolences to those who have suffered and lost their lives due to the new type of coronavirus infection in Japan and abroad, and our deepest sympathies to all those who have suffered and are fighting the disease.
I would also like to express my heartfelt gratitude to all the medical professionals who are working hard on the front lines of infectious disease countermeasures and treatment.
The Japan Pharmaceutical Manufacturers Association (JPMA) recognizes that the rapid research and development of effective and safe therapeutic agents and vaccines is an important means of bringing the new coronavirus infection to an end amid the global outbreak, and our member companies are committed to this and are working diligently to achieve this goal.
Specific directions of efforts include the diversion of existing drugs (drug repositioning), the creation of vaccines, and the creation of new therapeutic agents. All of these efforts require appropriate evaluation of efficacy and safety, and each company is making its best efforts to move forward with these efforts in a timely manner. The industry association is committed to promoting collaboration among industry, academia, and government in order to further accelerate these efforts.
We have decided to provide information on these efforts by our member companies through a special website entitled "New Coronavirus Infectious Disease Countermeasures". For details, please visit this website.
- Special website "Measures against new coronavirus infection
The End
For inquiries, please contact
Japan Pharmaceutical Manufacturers Association, Public Relations Department
- Phone
- 03-3241-0374